• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • Our Pillars
        • ARIKAYCE®
        • Brensocatib
        • TPIP
        • Early-Stage Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Sep 5, 2003
    Company Profile for Insmed Incorporated
    Company Profile for Insmed Incorporated
  • Jul 31, 2003
    Insmed Incorporated Reports Improved Financial Results for Second Quarter and First Half of 2003
    Insmed Incorporated Reports Improved Financial Results for Second Quarter and First Half of 2003
  • Jul 24, 2003
    Insmed Incorporated to Webcast Second Quarter Earnings Conference Call; Thursday, July 31, at 11:00 a.m. ET - 10:00 a.m. CT
    Insmed Incorporated to Webcast Second Quarter Earnings Conference Call; Thursday, July 31, at 11:00 a.m. ET - 10:00 a.m. CT
  • Jul 16, 2003
    Insmed Inc. Conludes Private Placement Led by Wells Fargo Securities Raising $1.9 Million More Than Previously Reported
    Insmed Inc. Conludes Private Placement Led by Wells Fargo Securities Raising $1.9 Million More Than Previously Reported
  • Jul 14, 2003
    Insmed Reports Positive Data to AACR with rhIGFBP-3 in Cancer
    Insmed Reports Positive Data to AACR with rhIGFBP-3 in Cancer
  • Jul 11, 2003
    Insmed Inc. Raises $12 Million in Private Placement of Common Stock Lead by Wells Fargo Securities
    Insmed Inc. Raises $12 Million in Private Placement of Common Stock Lead by Wells Fargo Securities
  • Jul 9, 2003
    Insmed Incorporated to Present Positive Oncology Data On rhIGFBP-3 at the Annual Meeting of the American Association of Cancer Research
    Insmed Incorporated to Present Positive Oncology Data On rhIGFBP-3 at the Annual Meeting of the American Association of Cancer Research
  • Jun 23, 2003
    Insmed Launches Pivotal Phase III Clinical Trial in GHIS; Data Analysis Planned for Early 2004
    Insmed Launches Pivotal Phase III Clinical Trial in GHIS; Data Analysis Planned for Early 2004
  • Jun 20, 2003
    Insmed Presents Positive Data on Lead Drug Candidate at Endocrine Society Annual Meeting; Study Shows Advantages of Company's rhIGF-I/rhIGFBP-3 In Treating Growth Disorder
    Insmed Presents Positive Data on Lead Drug Candidate at Endocrine Society Annual Meeting; Study Shows Advantages of Company's rhIGF-I/rhIGFBP-3 In Treating Growth Disorder
  • Jun 20, 2003
    Insmed Receives European Orphan Drug Designation For rhIGF-I/rhIGFBP-3; Product Will Have 10 Years of Market Exclusivity in Treatment of Growth Disorder
    Insmed Receives European Orphan Drug Designation For rhIGF-I/rhIGFBP-3; Product Will Have 10 Years of Market Exclusivity in Treatment of Growth Disorder
  • Jun 19, 2003
    Insmed Announces Management Reorganization; Ronald D. Gunn Promoted to Executive VP; Lewis Stuart Departs as VP Commercial Development
    Insmed Announces Management Reorganization; Ronald D. Gunn Promoted to Executive VP; Lewis Stuart Departs as VP Commercial Development
  • Jun 18, 2003
    Insmed to Present Lead Drug Candidate at the Endocrine Society Annual Meeting
    Insmed to Present Lead Drug Candidate at the Endocrine Society Annual Meeting
  • Jun 17, 2003
    Insmed Selected to Present to BIO 2003 Business Forum; Presentation to be Webcast Live
    Insmed Selected to Present to BIO 2003 Business Forum; Presentation to be Webcast Live
  • Jun 12, 2003
    Insmed to Report Positive Effects of rhIGF-I/rhIGFBP-3 In Adolescent Subjects with Type 1 Diabetes
    Insmed to Report Positive Effects of rhIGF-I/rhIGFBP-3 In Adolescent Subjects with Type 1 Diabetes
  • Jun 2, 2003
    Insmed Presents Data To ASCO Highlighting Potential Benefit Of rhIGFBP-3 in Cancer; rhIGFBP-3 Shown to Enhance Chemotherapy in Models of Human Breast Cancer
    Insmed Presents Data To ASCO Highlighting Potential Benefit Of rhIGFBP-3 in Cancer; rhIGFBP-3 Shown to Enhance Chemotherapy in Models of Human Breast Cancer
  • May 29, 2003
    Insmed to Present Positive Cancer Data to ASCO
    Insmed to Present Positive Cancer Data to ASCO
  • May 16, 2003
    Insmed Incorporated to Present at Techvest European Healthcare Conference
    Insmed Incorporated to Present at Techvest European Healthcare Conference
  • May 12, 2003
    Insmed Regains Full Compliance with Nasdaq National Market System Listing Requirements
    Insmed Regains Full Compliance with Nasdaq National Market System Listing Requirements
  • May 2, 2003
    Insmed Incorporated Announces Improved Financial Results for First Quarter 2003; Narrowing of Net Loss Exceeds Expectations; Cash Burn Rate Drops Sharply
    Insmed Incorporated Announces Improved Financial Results for First Quarter 2003; Narrowing of Net Loss Exceeds Expectations; Cash Burn Rate Drops Sharply
  • Apr 25, 2003
    Insmed Incorporated To Webcast First Quarter Earnings Conference Call; Friday, May 2, at 11:00 a.m. ET - 10:00 a.m. CT
    Insmed Incorporated To Webcast First Quarter Earnings Conference Call; Friday, May 2, at 11:00 a.m. ET - 10:00 a.m. CT
  • Apr 11, 2003
    Insmed Announces Publication of Investment Profile; Full Text Available on Corporate Website
    Insmed Announces Publication of Investment Profile; Full Text Available on Corporate Website
  • Apr 8, 2003
    Insmed Chairman to Provide Positive Outlook During CEOcast.com's Virtual Healthcare Conference
    Insmed Chairman to Provide Positive Outlook During CEOcast.com's Virtual Healthcare Conference
  • Apr 8, 2003
    Insmed Initiates Named Patient Programme For rhIGF-I/rhIGFBP-3, An Investigational Drug for Severe Growth Disorders
    Insmed Initiates Named Patient Programme For rhIGF-I/rhIGFBP-3, An Investigational Drug for Severe Growth Disorders
  • Apr 7, 2003
    Insmed Announces Improved Performance Expectations for First Quarter; Lead Product Candidate Prepared to Enter Phase III Trials
    Insmed Announces Improved Performance Expectations for First Quarter; Lead Product Candidate Prepared to Enter Phase III Trials
  • Apr 4, 2003
    Insmed Reports Positive Data with rhIGFBP-3 in Cancer; rhIGFBP-3 Improves Effect of Standard Cancer Therapies; rhIGFBP-3 Inhibits Tumor Growth up to 70%
    Insmed Reports Positive Data with rhIGFBP-3 in Cancer; rhIGFBP-3 Improves Effect of Standard Cancer Therapies; rhIGFBP-3 Inhibits Tumor Growth up to 70%
Show 5102550100 per page
  • «
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy